A phase 1b, open-label study of trebananib in combination with paclitaxel and carboplatin in patients with ovarian cancer receiving interval or primary debulking surgery

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

E. Eisenhauer, P. Therasse, Jan Bogaerts et al. · European Journal of Cancer · 2008 · 28.6K citations

Surgical Oncology, Recist Guideline, Medicine +9

Requisite Role of Angiopoietin-1, a Ligand for the TIE2 Receptor, during Embryonic Angiogenesis

Chitra Suri, Pamela F. Jones, Sybill Patan et al. · Cell · 1996 · 2.8K citations · Full text

Signal Transduction, Developmental Biology, Angiogenesis +10

Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer

Ignace Vergote, Claes G. Tropé, Frédéric Amant et al. · New England Journal of Medicine · 2010 · 2.5K citations · Full text

Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer

Robert A. Burger, Mark F. Brady, Michael A. Bookman et al. · New England Journal of Medicine · 2011 · 2.3K citations · Full text

A Phase 3 Trial of Bevacizumab in Ovarian Cancer

Timothy Perren, Ann Marie Swart, Jacobus Pfisterer et al. · New England Journal of Medicine · 2011 · 2.1K citations · Full text